COMP <GO>
TWIN vs TMO // EV/EBITDA & P/E VALUATION
Twin Disc Incorporated (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TWIN 3
— TMO 7
▲ EV/EBITDA & P/E VALUATION LEADER: TWIN
LAST: $25.29 (-0.71%) • MKT CAP: $367.7M
valuation
17.1x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWIN VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWIN | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 27.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.90% | 9.30% | -5.40 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.1x | 30.4x | -13.30 | TWIN | /valuation <GO> |
| Free Cash Flow Yield | 2.40% | 2.40% | 0.00 | TIE | /fcf-yield <GO> |
| Operating Margin | 3.30% | 17.40% | -14.10 | TMO | /operating-margins <GO> |
| Net Profit Margin | -0.60% | 15.10% | -15.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 15.50% | 3.90% | +11.60 | TWIN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.62% | 0.24% | +0.38 | TWIN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 4.50 | -1.37 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 62.9 | -21.41 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $367.7M | $262.22B | -$261.85B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWIN REV | TMO REV | TWIN GROSS % | TMO GROSS % | TWIN FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $340.7M | $44.56B | 27.6% | — | $8.8M | $6.29B |
| FY 2024 | $295.1M | $42.88B | 28.2% | — | $25.0M | $7.27B |
| FY 2023 | $0 | $42.86B | — | — | $22.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWIN // BETA —
TMO // BETA 0.94